Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45


HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL.

Cancer Cell. 2004 Nov;6(5):517-27.


HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?

Freeman MR.

Cancer Cell. 2004 Nov;6(5):427-8.


The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.

Hsu FN, Yang MS, Lin E, Tseng CF, Lin H.

Am J Physiol Endocrinol Metab. 2011 May;300(5):E902-8. doi: 10.1152/ajpendo.00610.2010. Epub 2011 Mar 1.


Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.

Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ.

Mol Cell Endocrinol. 2004 May 31;220(1-2):109-23.


17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Solit DB, Zheng FF, Drobnjak M, M√ľnster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.

Clin Cancer Res. 2002 May;8(5):986-93.


Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin.

Cinar B, De Benedetti A, Freeman MR.

Cancer Res. 2005 Apr 1;65(7):2547-53.


Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.

Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F.

Cancer Res. 2005 Nov 15;65(22):10585-93.


Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.

Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G, Verhoeven G, Morel L.

Biochem J. 2002 Sep 15;366(Pt 3):729-36.


Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.

Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.

Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30.


The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells.

Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G, Baldi E.

Steroids. 2004 Aug;69(8-9):549-52.


Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.


Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.

Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH, Sheng S.

J Cell Biochem. 2006 Aug 15;98(6):1408-23. Review.


Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.

Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C.

J Biol Chem. 2003 Dec 19;278(51):50902-7. Epub 2003 Oct 10.

Supplemental Content

Support Center